Tempest Therapeutics, Inc. (Nasdaq: TPST) announced its financial results for the year ended December 31, 2025, alongside a significant corporate update. The company reported a cash position of $7.7 million, down from $30.3 million at the end of 2024, primarily due to cash used in operating activities. Notably, Tempest completed a strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc., which is expected to enhance its pipeline of CAR-T cell therapy candidates. The acquisition includes TPST-2003, a clinical-stage dual-targeting CAR-T therapy, which has shown promising interim data in a Phase 1/2a trial for patients with relapsed/refractory multiple myeloma (rrMM). The data suggests a favorable safety and efficacy profile, positioning TPST-2003 as a potential differentiator in the CAR-T treatment landscape. The company anticipates initiating a U.S. registrational study for TPST-2003 later this year. Additionally, Tempest reported a net loss of $26.3 million for 2025, a decrease from $41.8 million in 2024, reflecting a strategic shift in operational focus. The company also announced leadership changes, with Matt Angel, Ph.D., appointed as Chief Executive Officer and President. This leadership transition is expected to drive the company's strategic vision forward as it navigates the evolving landscape of cancer therapeutics. Overall, the combination of financial results and strategic acquisitions positions Tempest Therapeutics for potential growth and innovation in the biotechnology sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.